Table 5.
1-Year Cardiovascular and Bleeding in Baseline HbA1c Subgroups
| Events | HbA1c<6.5% |
HbA1c≥6.5% |
P Value |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T+A (n = 79) | T (n = 73) | A (n = 81) | Total (n = 233) | P Value | T+A (n = 59) | T (n = 60) | A (n = 53) | Total (n = 172) | P Value | HbA1c <6.5% vs ≥6.5% | |
| MACE | 0 | 2 (2.7) | 4 (4.9) | 6 (2.6) | 0.124 | 2 (3.4) | 1 (1.7) | 4 (7.5) | 7 (4.1) | 0.260 | 0.409 |
| Cardiovascular death | 0 | 0 | 0 | 0 | 1 (1.7) | 0 | 2 (3.8) | 3 (1.7) | 0.207 | ||
| Myocardial infarction | 0 | 1 (1.4) | 2 (2.5) | 3 (1.3) | 1 (1.7) | 0 | 0 | 1 (0.6) | |||
| Stroke | 0 | 1 (1.4) | 2 (2.5) | 3 (1.3) | 0 | 1 (1.7) | 2 (3.8) | 3 (1.7) | |||
| Bleeding | 31 (39.2) | 8 (11) | 6 (7.4) | 46 (19.8) | <0.001 | 15 (25.4) | 10 (16.7) | 5 (9.4) | 30 (17.5) | 0.082 | 0.632 |
| Major | 2 (2.5) | 1 (1.4) | 0 | 3 (1.3) | 0.419 | 0 | 0 | 0 | 0 | - | 0.265 |
| Minor | 2 (2.5) | 0 | 0 | 2 (0.9) | 0.211 | 0 | 0 | 1 (1.9) | 1 (0.6) | 0.308 | 1.000 |
| Minimum | 28 (35.4) | 7 (9.6) | 6 (7.4) | 41 (17.6) | <0.001 | 15 (25.4) | 10 (16.7) | 4 (7.5) | 29 (16.9) | 0.039 | 0.846 |
Values are n (%).
A = aspirin; MACE = major adverse cardiovascular events; T = ticagrelor.